Form 4 for DGX Quest Diagnostics

Accepted 2026-02-12 00:00:00 ET · period of report 2026-01-28 · accession 0001022079-26-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-02-12	2026-02-10	DGX	Plewman Patrick	SVP for Diagnostic Services	S - Sale+OE	$204.00	-5,662	15.4K	-27%	-$1.16M
D	2026-02-12	2026-02-10	DGX	Plewman Patrick	SVP for Diagnostic Services	M - OptEx	$121.81	+5,662	21.0K	+37%	+$689.7K
D	2026-02-12	2026-01-28	DGX	Plewman Patrick	SVP for Diagnostic Services	A - Grant	$183.51	+48	15.4K	+0.3%	+$8,808
D	2026-02-12	2026-02-10	DGX	Plewman Patrick	SVP for Diagnostic Services	M - OptEx	$121.81	-5,662	0	-100%	-$689.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-02-10	S	D	5,662	$204.00	15,381	D	—	—
2	Common	Common Stock	2026-02-10	M	A	5,662	$121.81	21,043	D	—	—
3	Common	Common Stock	2026-01-28	A	A	48	$183.51	15,381	D	—	—	(F1) Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
4	Derivative	Non-Qualifed Stock Option (right to buy)	2026-02-10	M	D	5,662	$121.81	0	D	$121.81 · — to 2031-02-17	5,662 Common Stock	(F3) The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.